CN102702582A - Zeamays L. polysaccharide and preparation method and application thereof - Google Patents
Zeamays L. polysaccharide and preparation method and application thereof Download PDFInfo
- Publication number
- CN102702582A CN102702582A CN2011103484578A CN201110348457A CN102702582A CN 102702582 A CN102702582 A CN 102702582A CN 2011103484578 A CN2011103484578 A CN 2011103484578A CN 201110348457 A CN201110348457 A CN 201110348457A CN 102702582 A CN102702582 A CN 102702582A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- stigma maydis
- extraction
- corn silk
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a compound of zeamays L. polysaccharide, a preparation method, and an application of the zeamays L. polysaccharide in the preparation of medicaments for reducing blood sugar. The zeamays L. polysaccharide of the invention can be separated, extracted, and purified from zeamays L. by a simple and effective polysaccharide extraction technology and method. Pharmacological experiments show that the zeamays L. polysaccharide has significant in-vivo blood sugar reducing activity.
Description
Technical field
The present invention relates to the plant extract polysaccharide, more particularly, relate to a kind of corn silk polysaccharide its preparation method that extraction obtains from Stigma Maydis (Zea mays L.) and this corn silk polysaccharide are used for treating hypoglycemic medicine in preparation purposes.
Background technology
Stigma Maydis is style and the column cap of grass Zea mays Zea mays L..Medicinal the earliest record is shown in 1476 " the southern regions of the Yunnan Province wood grass ", is China's traditional Chinese medicines material, and " Chinese pharmacopoeia was recorded in 1977.Be " Ministry of Health of the People's Republic of China's medicinal material standard " 1985 editions medicinal herbs most in use kinds that (an one) includes.Stigma Maydis all has diuretic properties to people or rabbit, can increase the muriate output, and the insoluble part of its aqueous extract methyl alcohol is the strongest through dialysis person's diuretic properties, and no matter oral, subcutaneous or intravenous injection all has unusual effect.The Stigma Maydis preparation can promote bile excretion, reduces its viscosity, reduces its PORPHOBILIN content, thereby can be used as the cholangitis patient that choleretic is used for uncomplicated chronic cholecystitis, bile discharge obstacle.It can also the accelerate blood process of setting, increases prothrombing content in the blood, is applied to bladder and lithangiuria so can be used as the styptic hydragog(ue) of holding concurrently.Research report was once arranged about the hypoglycemic activity of corn silk polysaccharide, but this patent relates to wherein the reduction KK-A that corn silk polysaccharide most importantly has highly significant to abdominal injection tetraoxypyrimidine modeling mouse
yThe effect of diabetes B mouse blood sugar.
Because polysaccharide is the polarity macromolecular cpd, its extraction separation is very complicated, adopts boiling water, alkaline solution to extract mostly.Free protein in the extracting solution is mainly removed with three kinds of methods such as Sevage method, trichloroacetic acid method and Freon 113 method.Small molecular weight impurity can be removed with dialysis method.
The purification process of polysaccharide is a lot, and the distribution precipitator method, salting-out process, metal complex method, quaternary salt deposit method are arranged, DEAE-Mierocrystalline cellulose method and other various dissimilar gel filtration chromatography methods etc., and colorimetric methods such as employing sulfuric acid-phynol method are measured polysaccharide content.
Mellitus are the very complicated endocrine metabolism property diseases of a kind of cause of disease, and its basic pathology physiology is the hypoinsulinism of absoluteness or relativity; And the β cell reduces the susceptibility of Regular Insulin, thereby causes water, the metabolic disturbance of electrolyte of sugar, protein, fat and secondary.Can cause acid base imbalance when serious.Its typical characteristics is: hyperglycemia, glucose in urine, glucose tolerance reduction and insulin release test are unusual.Clinical manifestation for many drinks, many foods, diuresis, polydipsia, be prone to famine, become thin, symptom such as fatigue and weak; The diabetic subject is owing to inherited genetic factors, environmental factors, life factor, mental element, cause the immune function of human body obstacle, causes that interleukin-is reactive to be increased, and promotes islet cells endolymph cellular infiltration; The cell that soaks into produces a kind of antagonism insulin function infringement factor lymph and lives plain; The lymph plain beta Cell of islet blood circulation that hinders alive kills and wounds beta Cell of islet and sugar carrier gene, destroys each link of insulin secretion, drainage and transhipment; Cause the infringement of islet function, cause mellitus and diabetic complication.Diabetes B is called non insulin dependent diabetes more, and sickness rate accounts for 90% of diabetic sum; The age of onset majority is more than 35 years old.
Summary of the invention
The present invention utilizes simple and effective polysaccharide extracting process and method, is that raw material has obtained a kind of corn silk polysaccharide mixture with the Stigma Maydis.Pharmacological evaluation shows that corn silk polysaccharide has blood sugar regulation function and corresponding hypoglycemic activity.Therefore corn silk polysaccharide is expected to exploitation becomes a kind of as hypoglycemic healthcare product or medicine or assist a ruler in governing a country medicine and be used for clinical.
Therefore, one object of the present invention is to provide a kind of molecular weight ranges, sugar to form clear and definite corn silk polysaccharide.Another object of the present invention provides a kind of method for preparing corn silk polysaccharide.
A further object of the present invention provides a kind of hypoglycemic pharmaceutical composition that is used to treat; It comprises 40-4; Corn silk polysaccharide in the 000mg/kg/d effective dosage ranges is as effective constituent, and preferably, it can further contain pharmaceutically acceptable carrier and auxiliary material.
Another purpose of the present invention provides corn silk polysaccharide is used for treating hypoglycemic medicine in preparation purposes.
Among the present invention, the sugar of said corn silk polysaccharide consists of rhamnosyl, pectinose, wood sugar, seminose, semi-lactosi and glucose.Its mol ratio is: Rha: Ara: Xyl: Man: Gla: Glu=0.25: 0.86: 0.81: 0.47: 0.84: 1.22; Molecular-weight average is 42, and 095Da, molecular weight ranges are 1,500-100,000Da.
According to another object of the present invention, the invention provides the method for preparing corn silk polysaccharide, mainly be from the style of grass Zea mays Zea mays L. and column cap, to carry out separation and Extraction and purifying, comprise the steps:
(1) get exsiccant Stigma Maydis medicinal material, the alcohol immersion degreasing with 95% (cold soaking ethanol did not have medicinal material to get final product) is changed three times, and immersion finishes, and places the room temperature ventilation to dry the gained solids, extracts then.The 1kg starting material add 10L tap water heated and boiled at every turn, and extraction time is 2～3 hours, and with sugared content in the phenolsulfuric acid method Detection and Extraction liquid, not obvious to the sugar reaction, extract altogether 6 times; Concentrated extracting solution, cooling.Add equal-volume 30% (W/V) trichoroacetic acid(TCA) solution, making its final concentration is 15% (W/V);
Use 10%NaOH to be neutralized to pH after (2) 4 ℃ of deproteinated and be 7.0 to 8.0, centrifugal.Supernatant was to flowing water dialysis two days, and dialyzate is concentrated into 2-3L, added 3 times of amount 95% ethanol sedimentations, left standstill, and precipitated centrifugal.With absolute ethanol washing back oven dry for several times, obtain Stigma Maydis crude polysaccharides;
Wherein, the alcoholic solution described in the step (1) is 95% ethanol, and ground uses alcoholic solution to soak for 95% alcohol immersion degreasing three times.
The condition of the boiling water extraction described in the step (1) is: add about 10L zero(ppm) water, extraction time is 2～3 hours at every turn, and with sugared content in the phenolsulfuric acid method Detection and Extraction liquid, extracts 3～5 times, preferably extracts 6 times.Dialysis condition described in the step (1) is: adopt flowing water dialysis 2 days.
In a preferred embodiment of the invention, the preparation corn silk polysaccharide comprises the steps:
(1) get exsiccant Stigma Maydis medicinal material, the alcohol immersion degreasing with 95% (cold soaking ethanol did not have medicinal material to get final product) is changed three times, and immersion finishes, and places the room temperature ventilation to dry the gained solids; Extract then, the 1kg starting material add 10L tap water heated and boiled at every turn, and extraction time is 2～3 hours, and with sugared content in the phenolsulfuric acid method Detection and Extraction liquid, not obvious to the sugar reaction, extract altogether 6 times; Concentrated extracting solution, cooling.Add equal-volume 30% (W/V) trichoroacetic acid(TCA) solution, making its final concentration is 15% (W/V), and 4 ℃ of deproteinated use 10%NaOH to be neutralized to pH afterwards and are 7.0 to 8.0, and are centrifugal.Supernatant was to flowing water dialysis two days, and dialyzate is concentrated into 2-3L, added 3 times of amount 95% ethanol sedimentations, left standstill, and precipitated centrifugal.With absolute ethanol washing back oven dry for several times, obtain Stigma Maydis crude polysaccharides.
According to a further object of the present invention; The invention provides a kind of hypoglycemic pharmaceutical composition that is used to treat, it comprises 40-4, and the Stigma Maydis crude polysaccharides of 000mg/kg/d effective dosage ranges is as effective constituent; And preferably, it can further contain pharmaceutically acceptable carrier and auxiliary material.
But Stigma Maydis crude polysaccharides oral administration of the present invention or without the mouth administration.During the oral administration administration; Can be directly or this compounds is mixed with conventional medicinal adjuvant (like vehicle, disintegrating agent, tamanori, lubricant, inhibitor, seed dressing agent, tinting material, perfume compound, tensio-active agent etc.), be made into forms such as granule, capsule, tablet; During non-oral administration, can injection liquid, form administration such as infusion solution or suppository.When preparing above-mentioned preparation, can use conventional preparation technique.
According to another purpose of the present invention, the invention provides Stigma Maydis crude polysaccharides is used for treating hypoglycemic medicine in preparation purposes.The present invention utilizes a kind of simple and effective polysaccharide extracting process and method, is the Stigma Maydis crude polysaccharides that raw material has obtained a kind of homogeneous with the Stigma Maydis, and pharmacological evaluation shows that Stigma Maydis crude polysaccharides has blood glucose regulation function and corresponding hypoglycemic activity.Therefore Stigma Maydis crude polysaccharides is expected to exploitation becomes a kind of as hypoglycemic healthcare product or medicine or assist a ruler in governing a country medicine and be used for clinical.
Description of drawings
Fig. 1 is the extraction separation purifying schema according to the Stigma Maydis crude polysaccharides of an embodiment of the invention.
Fig. 2 schemes according to the ir spectra of the Stigma Maydis crude polysaccharides of an embodiment of the invention (IR).
Fig. 3 schemes according to the high-efficient liquid phase chromatogram of the Stigma Maydis crude polysaccharides of an embodiment of the invention (HPLC).
Fig. 4 is sugared compositional analysis figure (GC) figure according to the Stigma Maydis crude polysaccharides of an embodiment of the invention.
Embodiment
Below in conjunction with embodiment the present invention is done further elaboration, following embodiment is only described the present invention by way of example.Clearly, those of ordinary skills can carry out various accommodations and modification to the present invention in scope of the present invention and essence.Need be appreciated that, this invention is intended to be encompassed in the flexible and modification that comprises in the appended claims.
Instrument:
Tianjin, island SIL-20A automatic sampler, LC-20AD HPP, CTO-20A column oven, SPD-20A ultraviolet-visible detector, CBM-20A central controller and GPC data processing software.(exclusion limit is respectively 4 * 10 for 7.8mm * 300mm, hydroxylated polymethylmethacrylate with Ultrahydrogel 2000 for two polysaccharide special gel chromatographic column Ultrahydrogel 500
5With 7 * 10
6Da) and pre-column Ultrahydrogel Guard Column (6 μ m, 6x40mm) series connection; Chromatographic condition: with Buffer (the mixed 1L that is settled to of 7.32g potassium hydrogenphosphate and 0.4g potassium primary phosphate) is moving phase, and column temperature is 35 ℃, and flow velocity is PM 0.5ml, and sample size is 20 μ l.
Automatic Fraction Collector of BSZ-100 and HL-2 constant flow pump (west, Shanghai, Qingpu, Shanghai instrument plant); Labconco 6 type lyophilizers (Britain Labconco company); The CR-22G of Hitachi type supercentrifuge (Japanese Hitachi company); Electric heating constant temperature air dry oven (going up the grand experimental installation of Nereid ltd), EYELA-N1100 type Rotary Evaporators, UV1000 ultraviolet-visible pectrophotometer (Shanghai Techcomp Instrument Ltd.).
Medicine and reagent:
The Stigma Maydis entity is available from the pharmacy in the Hu Qingyu Pharmaceutical Workshop, Shanghai.
(molecular retention is 3 to dialysis tubing, and 500Da), other reagent sources are traditional Chinese medicines group in Shanghai.
The preparation of embodiment 1 corn silk polysaccharide:
Get 1 kilogram of Stigma Maydis (available from Hu Qingyu Pharmaceutical Workshop, Shanghai pharmacy), the alcohol immersion with 95% 3 times is dried after the end.Dry product after the degreasing is used boiling water extraction, adds about 10 liters in water at every turn, and extraction time is 2-3 hour, and is not obvious until the sugar reaction with the sugared content of phenol sulfuric acid process Detection and Extraction liquid, extracts altogether 7 times.Each extracting solution is merged, finally be concentrated into about 2L, add equal-volume 30% (W/V) trichoroacetic acid(TCA) solution, making its final concentration is 15% (W/V); In 4 ℃ of deproteinated 3h, transfer pH to neutral with 10%NaOH afterwards, 12000rpm is centrifugal, gets supernatant; Supernatant was to flowing water dialysis two days, and dialyzate is concentrated into about 2L, added 3 times of amount 95% ethanol sedimentations, hold over night; 12,000rpm is centrifugal, gets deposition.After absolute ethyl alcohol and acetone wash successively, in 50 ℃ of heat dryings, corn silk polysaccharide, the brown solid.
EXPERIMENTAL EXAMPLE
Experimental example 1 pharmacological evaluation:
1, Stigma Maydis is to diabetes B mouse blood sugar reducing function
1.1 experiment material
(a) raw material: corn silk polysaccharide, Vandyke brown dry powder, (Shanghai) Co., Ltd. provides by the farsighted moral biological medicine science and technology of match jade-like stone, and-20 degree are preserved.
(b) experiment mice: KK-A
yMouse is a kind of hair color gene (ay) mutant diabetic mice; The ay gene not only influences the hair color of mouse but also can cause metabolism disorder; The unusual syndromes of metabolism such as obesity, hyperglycemia, lipid metabolism disorders and hyperinsulinemia occur, its morbidity is on the basis of inheritance susceptible, to add environmental factors and bring out, and shows very similar with human diabetes B; Be a kind of ideal people type diabetes animal model, be the typical model of insulin resistant.
KK-A
y24 of diabetic mices, male, body weight 26 ± 1g; Available from Beijing China Fukang biotech inc, all raise with high lipid food (providing) by Beijing China Fukang biotech inc, feed with sterilization plastics mouse cage; Freely drink water, the Animal House temperature is controlled at 20-25 degree, humidity 55-65%; Illumination 10-12h/d, one week of mouse cage is changed 2-3 time.
(c) laboratory apparatus: blood glucose meter, remarkable type blood glucose meter
the Luo Shi blood sugar test paper of Luo Shi
1.2 experimental technique
(a) animal is divided into 1 dosage experiments group and 2 control groups at random, 8 every group.Experimental group is with Stigma Maydis 400mg/kg/d, and control group is irritated 6 weeks of stomach with continuous normal saline.Irritating the gastric liquid volumetric quantity is 0.1ml/10g mouse body weight.
(b) per two weeks are measured mouse fasting plasma glucose 1 time, and fasting 3hr before measuring cuts tail and gets blood.
Fasting blood sugar is respectively organized in table 1 test
Table 1 shows that when the experiment beginning, each treated animal fasting plasma glucose does not have significant difference; Irritate stomach after 2 weeks, significantly reduce (equal p＜0.05) when the fasting plasma glucose of Stigma Maydis 400mg/kg administration group begins with the concurrent control group; Blood glucose value does not have significant difference again with contrast ratio after several afterwards all administrations.
Experimental example 2 pharmacological evaluation:
1. Stigma Maydis is to the influence experiment of diabetic mice OGTT and body weight
1.1 experiment material
(a) raw material: corn silk polysaccharide, Vandyke brown dry powder, (Shanghai) Co., Ltd. provides by the farsighted moral biological medicine science and technology of match jade-like stone, and-20 degree are preserved.
(b) experiment mice: KK-A
y24 of diabetic mices, male, body weight 26 ± 1g; Available from Beijing China Fukang biotech inc, all raise with high lipid food (providing) by Beijing China Fukang biotech inc, feed with sterilization plastics mouse cage; Freely drink water, the Animal House temperature is controlled at 20-25 degree, humidity 55-65%; Illumination 10-12h/d, one week of mouse cage is changed 2-3 time.
(c) laboratory apparatus: blood glucose meter, remarkable type blood glucose meter
the Luo Shi blood sugar test paper of Luo Shi
1.2 experimental technique
(a) time respectively organized in the 4th week mouse do the sugar tolerance experiment (oral glucose tolerance test, OGTT).Mouse empty stomach 3h can freely drink water before the OGTT.OGTT same day is dissolved in glucose respectively in the sterile purified water by the 2g/kg body weight, and 10min gave Glucose Liquid after each group gave medicine respectively, irritates gastric liquid volumetric quantity 0.1ml/10g mouse body weight, observe when irritating stomach and irritate stomach after the change of blood sugar of 30min, 1h, 2h.
When (b) each group of experiment is around administration, give 2g/kg glucose on an empty stomach, detect the change of blood sugar when giving sugar back 30min, 60min and 120min.Fasting 3hr before measuring cuts tail and gets blood.
The OGTT value is respectively organized in table 2 test
Table 2 shows, irritates the OGTT result of stomach after 4 weeks and do not see and respectively organize blood glucose value and control group there were significant differences.(c) eight weeks of successive administration are respectively organized in experiment, and per two weeks are measured body weight once, observe the influence of medicine to each experimental group body weight.
Each experimental group changes of weight table of table 3
Table 3 shows that during 2 weeks, Stigma Maydis 400mg/kg administration group body weight has trend p＜0.05 that alleviates than control group).But body weight begins again to recover after several weeks of administration afterwards, does not see that other are xicity related.KK-A
yDiabetic mice is irritated gastric liquid volumetric quantity (ml) at every turn and is 0.01 times of mouse body weight (g) in the process of Stigma Maydis of feeding, and digestive function reduction phenomenon does not appear in mouse after 6 weeks, and body weight and control group do not have significant difference.
Experimental example 3 pharmacological evaluation:
1. Stigma Maydis is to the influence experiment of postprandial blood sugar
1.1 experiment material
(a) raw material: corn silk polysaccharide, Vandyke brown dry powder, (Shanghai) Co., Ltd. provides by the farsighted moral biological medicine science and technology of match jade-like stone, and-20 degree are preserved.
(b) experiment mice: KK-A
y24 of diabetic mices, male, body weight 26 ± 1g; Available from Beijing China Fukang biotech inc, all raise with high lipid food (providing) by Beijing China Fukang biotech inc, feed with sterilization plastics mouse cage; Freely drink water, the Animal House temperature is controlled at 20-25 degree, humidity 55-65%; Illumination 10-12h/d, one week of mouse cage is changed 2-3 time.
(c) laboratory apparatus: blood glucose meter, remarkable type blood glucose meter
the Luo Shi blood sugar test paper of Luo Shi
(d) by experiment 1 method, after 8 weeks of administration, each group of experiment gives drug-treated under non-fasting state, measures the change of blood sugar behind 0min after the administration, 30min, 60min, the 120min respectively.
Table 4 postprandial plasma glucose level after each 8 week of experimental group administration
Claims (9)
1. the mixture with corn silk polysaccharide is characterized in that the sugar of this polysaccharide compound consists of: rhamnosyl, pectinose, wood sugar, seminose, semi-lactosi and glucose.Its mol ratio is: Rha: Ara: Xyl: Man: Gla: Glu=0.25: 0.86: 0.81: 0.47: 0.84: 1.22; Molecular-weight average is 42, and 095Da, molecular weight ranges are 1,500-100,000Da.
2. a method for preparing corn silk polysaccharide as claimed in claim 1 comprises the steps:
(1) gets Stigma Maydis crude drug (1kg); With 95% alcohol immersion degreasing three times, natural drying at room temperature after the degreasing, dried Stigma Maydis crude drug is with boiling water extraction 4 to 6 times; Each 2h is to 3h; The Stigma Maydis crude drug adds water 8 to 10L with the ratio of each amount of water for the 1kg medicinal material, and the sugared content of sulfuric acid-phynol method Detection and Extraction liquid is not obvious until the sugar reaction.
(2) each extracting solution is merged, finally be concentrated into 2L, add equal-volume 30% (W/V) trichoroacetic acid(TCA) solution, making its final concentration is 15% (W/V); 4 ℃ of deproteinated use 10%NaOH to be neutralized to pH after 3 hours to be 7.0 to 8.0, and centrifugal, supernatant was to flowing water dialysis two days; Dialyzate is concentrated into 2-3L, adds 3 times of amount 95% ethanol sedimentations, leaves standstill; Precipitate centrifugally,, obtain Stigma Maydis crude polysaccharides with absolute ethanol washing back oven dry for several times.
3. method according to claim 2 is characterized in that, the alcoholic solution described in the step (1) is 95% ethanol, preferably uses alcoholic solution to soak for 95% alcohol immersion degreasing three times.
4. method according to claim 2 is characterized in that, the condition of the boiling water extraction described in the step (1) is: solid-liquid ratio (1: 10); Add about 10L zero(ppm) water, extraction time is 2～3 hours at every turn, and with sugared content in the phenolsulfuric acid method Detection and Extraction liquid; Extract 5～7 times, preferably extract 6 times.
5. method according to claim 2 is characterized in that, the polysaccharide method for removing protein described in the step (2) is 30% (W/V) trichloroacetic acid method, and condition is: 4 ℃ of following deproteinated are after 3 hours, and with the 10%NaOH neutralization, Ph transfers to pH and is 7.0 to 8.0, and is centrifugal.
6. method according to claim 2 is characterized in that, the dialysis condition described in the step (2) is: adopt flowing water dialysis 2 days.
7. method according to claim 2 is characterized in that, comprises the steps:
Get exsiccant Stigma Maydis medicinal material, the alcohol immersion degreasing with 95% (cold soaking ethanol did not have medicinal material to get final product) is changed three times, and immersion finishes; Place the room temperature ventilation to dry the gained solids, extract then, the 1kg starting material add 10L tap water heated and boiled at every turn, and extraction time is 2～3 hours; And with sugared content in the phenolsulfuric acid method Detection and Extraction liquid, not obvious to the sugar reaction, extract concentrated extracting solution altogether 6 times; Cooling adds equal-volume 30% (W/V) trichoroacetic acid(TCA) solution, and making its final concentration is 15% (W/V), and it is 7.0 to 8.0 that 4 ℃ of following deproteinated used 10%NaOH to be neutralized to pH afterwards in 3 hours; Centrifugal, supernatant was to flowing water dialysis two days, and dialyzate is concentrated into 2-3L, added 3 times of amount 95% ethanol sedimentations; Leave standstill, precipitate centrifugally,, obtain Stigma Maydis crude polysaccharides with absolute ethanol washing back 50 ℃ of oven dry for several times.
8. polysaccharide compound, it comprises 40-4, in the 000mg/kg/d effective dosage ranges, the described corn silk polysaccharide of claim 1 is as effective constituent, and preferably further contains pharmaceutically acceptable carrier and auxiliary material.
9. the described corn silk polysaccharide of claim 1 is used for treating the purposes of hypoglycemic medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103484578A CN102702582A (en) | 2011-11-07 | 2011-11-07 | Zeamays L. polysaccharide and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103484578A CN102702582A (en) | 2011-11-07 | 2011-11-07 | Zeamays L. polysaccharide and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102702582A true CN102702582A (en) | 2012-10-03 |
Family
ID=46895658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103484578A Pending CN102702582A (en) | 2011-11-07 | 2011-11-07 | Zeamays L. polysaccharide and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102702582A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103012614A (en) * | 2012-12-29 | 2013-04-03 | 保龄宝生物股份有限公司 | Extraction method of corn husk active polysaccharide |
| CN105399850A (en) * | 2015-12-08 | 2016-03-16 | 吉林化工学院 | Preparation method, product and application of corn husk polysaccharide |
| CN105496841A (en) * | 2014-09-26 | 2016-04-20 | 上海家化联合股份有限公司 | Preparation method and moisture retention effect of cistanche bulb extract |
| CN105496842A (en) * | 2014-09-26 | 2016-04-20 | 上海家化联合股份有限公司 | Preparation method and anti-oxidation effect of cistanche deserticola bulb extract |
| CN105496840A (en) * | 2014-09-26 | 2016-04-20 | 上海家化联合股份有限公司 | Preparation method and skin aging-delaying effect of cistanche bulb extract |
| CN105878331A (en) * | 2016-05-31 | 2016-08-24 | 无限极（中国）有限公司 | Polysaccharide composition and preparation method and application thereof |
| CN105963567A (en) * | 2016-07-01 | 2016-09-28 | 大连海洋大学 | Medicine for treating diabetes and preparation method thereof |
| CN106434787A (en) * | 2016-06-21 | 2017-02-22 | 吉林大学 | Corn peel polysaccharide compound, preparation method thereof and medicinal use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101658528A (en) * | 2009-09-25 | 2010-03-03 | 吉林化工学院 | Application of corn silk polysaccharide on preparation of medicine for curing hyperlipidemia |
| CN101914166A (en) * | 2010-08-25 | 2010-12-15 | 吉林化工学院 | Technical method for decoloring and deproteinizing corn stigma polysaccharide |
-
2011
- 2011-11-07 CN CN2011103484578A patent/CN102702582A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101658528A (en) * | 2009-09-25 | 2010-03-03 | 吉林化工学院 | Application of corn silk polysaccharide on preparation of medicine for curing hyperlipidemia |
| CN101914166A (en) * | 2010-08-25 | 2010-12-15 | 吉林化工学院 | Technical method for decoloring and deproteinizing corn stigma polysaccharide |
Non-Patent Citations (3)
| Title |
|---|
| 《中国农业大学学报》 20100815 贾亚敏等 玉米须多糖理化特性及免疫调节活性研究 第20-24页 第15卷, 第4期 * |
| 贾亚敏等: "玉米须多糖理化特性及免疫调节活性研究", 《中国农业大学学报》 * |
| 赵文竹等: "玉米须多糖纯化工艺的研究", 《食品工业科技》 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103012614A (en) * | 2012-12-29 | 2013-04-03 | 保龄宝生物股份有限公司 | Extraction method of corn husk active polysaccharide |
| CN105496840B (en) * | 2014-09-26 | 2018-11-13 | 上海家化联合股份有限公司 | A kind of preparation method and delay skin aging effect of Herba Cistanches bulb extract |
| CN105496841A (en) * | 2014-09-26 | 2016-04-20 | 上海家化联合股份有限公司 | Preparation method and moisture retention effect of cistanche bulb extract |
| CN105496842A (en) * | 2014-09-26 | 2016-04-20 | 上海家化联合股份有限公司 | Preparation method and anti-oxidation effect of cistanche deserticola bulb extract |
| CN105496840A (en) * | 2014-09-26 | 2016-04-20 | 上海家化联合股份有限公司 | Preparation method and skin aging-delaying effect of cistanche bulb extract |
| CN105496841B (en) * | 2014-09-26 | 2018-10-30 | 上海家化联合股份有限公司 | A kind of preparation method and moisture-keeping function of Herba Cistanches bulb extract |
| CN105496842B (en) * | 2014-09-26 | 2018-11-13 | 上海家化联合股份有限公司 | A kind of preparation method and antioxidation of Herba Cistanches bulb extract |
| CN105399850A (en) * | 2015-12-08 | 2016-03-16 | 吉林化工学院 | Preparation method, product and application of corn husk polysaccharide |
| CN105878331A (en) * | 2016-05-31 | 2016-08-24 | 无限极（中国）有限公司 | Polysaccharide composition and preparation method and application thereof |
| CN106434787A (en) * | 2016-06-21 | 2017-02-22 | 吉林大学 | Corn peel polysaccharide compound, preparation method thereof and medicinal use thereof |
| CN106434787B (en) * | 2016-06-21 | 2019-07-09 | 吉林大学 | A kind of corn peel polysaccharide compound and preparation method and medical application |
| CN105963567A (en) * | 2016-07-01 | 2016-09-28 | 大连海洋大学 | Medicine for treating diabetes and preparation method thereof |
| CN105963567B (en) * | 2016-07-01 | 2019-08-30 | 大连海洋大学 | The drug and preparation method for treating diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102702582A (en) | Zeamays L. polysaccharide and preparation method and application thereof | |
| CN105920067A (en) | Sunflower calathide extract containing polysaccharide, flavonoid and alkaloid and preparation method of sunflower calathide extract | |
| CN115364170B (en) | Sugar metabolism regulator and preparation method and application thereof | |
| CN112961262A (en) | Passiflora edulis pericarp acidic polysaccharide, preparation method and application thereof | |
| CN105504076B (en) | A kind of radix tetrastigme root tuber polysaccharide acted on antipyretic and anti-inflammatory and application thereof | |
| CN104922176A (en) | Application of flos chrysanthemi indici extract | |
| CN111568948A (en) | Application of mulberry extract in preparing medicine for improving pancreatic islet function | |
| CN102813747B (en) | Traditional Chinese medicine for treating systemic lupus erythematosus | |
| CN1861637A (en) | Preparation process of Huai Chinese yam polysaccharose and use thereof | |
| CN110559403A (en) | Traditional Chinese medicine composition for preventing and treating hyperuricemia and preparation method and application thereof | |
| CN101444599B (en) | Corn silk extract and preparation method thereof and application thereof in preparing drugs for treating gout | |
| CN105055496A (en) | Pharmaceutical composition for treating diabetes mellitus | |
| CN114848745A (en) | Chicory and gardenia beverage and preparation method thereof | |
| CN102698096B (en) | Composition of traditional Chinese medicine extracts and preparation method and application thereof | |
| CN105168300A (en) | Pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN110314160A (en) | Berbamine prevents and treats the application in medicine for treating diabetic nephropathy in preparation | |
| CN112979839A (en) | Preparation method of passion flower leaf acidic polysaccharide | |
| CN106974917B (en) | Application of exodermis poria triterpene in preparation of medicine for treating nephropathy | |
| CN101816698A (en) | Composition for preventing and curing metabolism disturbance syndrome | |
| CN107126450B (en) | A Chinese medicinal preparation containing extract and effective substance, and its preparation method and application | |
| CN117815261B (en) | New medical application of saw palmetto fruit extract and soft capsule thereof | |
| CN115671219B (en) | Traditional Chinese medicine composition for treating gout and preparation method and application thereof | |
| CN101618157B (en) | Medicine composition for treating autumn-dryness cold and preparation method thereof | |
| CN106727958A (en) | It is a kind of to treat pharmaceutical composition of alcoholic hepatitis and preparation method thereof | |
| JP2006213607A (en) | Uric acid value-decreasing agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121003 |